Skip to main content
. 2024 Mar 13;43(19):1411–1430. doi: 10.1038/s41388-024-03000-9

Fig. 5. p53 deficiency induces mTOR dependency.

Fig. 5

A mTORC1/mTORC2 phospho-protein expression (size) and z - score (color) of NF1-MET and NF1-P53 tumors (6 animals/group). B Contrast estimates +/− SE of mTORC1/mTORC2 phospho-protein expression in NF1-P53 tumors compared to NF1-MET tumors. Color indicates P-value. C Percent viability of NF1-MET, NF1-MET;sgP53, and NF1-P53 cells after 72 h of everolimus (20 nM) or combination (everolimus 20 nM, trametinib 40 nM) treatment. D Phospho-S6RP expression measured over time by RPPA after vehicle (DMSO) or everolimus (100 nM) treatment. Images (E) and flow cytometry analysis (F) of GFP labeled NF1-MET and RFP labeled NF1-MET;sgP53 cells after 3 and 5 days of treatment with vehicle (DMSO), everolimus (20 nM), or combination everolimus (20 nM) and trametinib (40 nM). G Expression (relative to the housekeeping gene PPIA) of cell fate markers by qRT-PCR upon treatment with combination everolimus (20 nM) and trametinib (40 nM). See also Supplementary Fig. 9E. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.